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Tumor vessel dysfunction is a pivotal event in cancer progression. Using an in vivo neovascularization model, 
we identified G protein–coupled receptor kinase 2 (GRK2) as a key angiogenesis regulator. An impaired 
angiogenic response involving immature vessels was observed in mice hemizygous for Grk2 or in animals with 
endothelium-specific Grk2 silencing. ECs isolated from these animals displayed intrinsic alterations in migra-
tion, TGF-β signaling, and formation of tubular networks. Remarkably, an altered pattern of vessel growth 
and maturation was detected in postnatal retinas from endothelium-specific Grk2 knockout animals. Mouse 
embryos with systemic or endothelium-selective Grk2 ablation had marked vascular malformations involving 
impaired recruitment of mural cells. Moreover, decreased endothelial Grk2 dosage accelerated tumor growth 
in mice, along with reduced pericyte vessel coverage and enhanced macrophage infiltration, and this trans-
formed environment promoted decreased GRK2 in ECs and human breast cancer vessels. Our study suggests 
that GRK2 downregulation is a relevant event in the tumoral angiogenic switch.
Introduction
The homeostasis and growth of vertebrate organisms requires a 
complex vascular network, necessary to deliver oxygen and nutri-
ents to tissues and to allow waste disposal and immune cell sur-
veillance (1). The process known as sprouting angiogenesis takes 
place during embryonic development to expand vasculogenic plex-
uses and postnatally for wound-healing repair and tissue remodel-
ing. However, abnormal angiogenesis can also fuel inflammatory 
and tumoral diseases (2). The complex angiogenic response com-
prises finely orchestrated sequential steps (activation, resolution, 
and maturation) and is initiated and regulated by manifold factors 
from the VEGF, FGF, or PDGF families as well as by cytokines and 
chemokines (1, 3). Angiogenesis is triggered when quiescent ECs 
in preexisting vessels sense proangiogenic signals (such as VEGF, 
FGF, or sphingosine-1-phosphate [S1P]) and loose their intercel-
lular junctions and when their basement membrane is degraded. 
Activated ECs guided by complex chemoattractant gradients of 
such proangiogenic factors proliferate and migrate out of the ves-
sel wall. The resolution phase of sprouting includes cessation of 
EC migration and proliferation, restoration of cell-cell junctions 
for barrier function, PDGF-BB– and CXCL12-mediated recruit-
ment of pericytes in order to stabilize the endothelial wall, and 
reconstitution of the basement membrane (1).
Chemokines and TGF-β signaling play an important and multi-
faceted role in the timely coordination of activation and resolution 
phases required for the successful formation of functional, mature 
neovessels by recruiting stromal proangiogenic cells and also by 
directly modulating both endothelial and pericyte functions (3, 4). 
In particular, TGF-β exerts positive and negative effects on the 
angiogenic process in a context-dependent way (4, 5). Such a 
proproliferative-to-antiproliferative/promigratory-to-antimigra-
tory signaling switch of TGF-β might relate to actions through 
2 distinct receptors, ALK1 and ALK5, coexpressed in ECs in cer-
tain conditions (4). The precise role of TGF-β in angiogenesis may 
depend on local cues, cell-cell interactions, and modulating factors 
impacting on ALK1/ALK5 interplay that need to be identified.
G protein–coupled receptor kinase 2 (GRK2) is a ubiquitous, 
essential protein kinase that is emerging as an integrative node in 
many signaling networks (6, 7). GRKs were initially identified as 
key players in the modulation of GPCRs. GRK-mediated phosphor-
ylation of ligand-occupied receptors leads to binding of β-arrestins, 
which in turn promotes GPCR desensitization and internalization 
(8). Besides such a canonical role, GRK2 can also initiate alternative 
signaling pathways and participate in cellular processes related to 
cell cycle progression, survival, or cell migration by phosphorylat-
ing and interacting with non-GPCR partners (7).
Interestingly, the GRK2 “interactome” in different cell types 
includes several actors in vascular homeostasis and remodeling (3, 9). 
Besides regulating chemokine GPCRs, GRK2 phosphorylates PDGF 
receptors (10) and also modulates TGF-β signaling in epithelial 
cells (11) or cardiac fibroblasts (12). GRK2 inhibits PDGF-depen-
dent chemotactic signaling in VSMCs (13) and modulates both 
vasoconstrictory and vasodilatory responses of VSMCs (14, 15), 
whereas increased GRK2 attenuates NO production by sinusoidal 
ECs in the context of liver injury (16). However, the role of GRK2 
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Figure 1
GRK2 deficiency results in an impaired in vivo angiogenesis, despite effective EC activation. (A) Matrigel implants mixed with the indicated 
stimuli or vehicle were injected into WT (Grk2+/+) or global hemizygous (Grk2+/–) mice, and hemoglobin content was quantified as described in 
the Methods. The angiogenic response data (calculated as fold over control conditions) were obtained from 9 to 12 animals for each condition 
in 3 to 4 independent experiments. (B) GRK2 downregulation does not compromise the S1P-induced activation of ERK1/2 and AKT pathways 
in MLECs. Data from 3 to 4 independent experiments are shown. Representative blots are shown. (C and D) GRK2 downmodulation enhances 
the PI3K-dependent directed cell migration of ECs in response to fibronectin (FN) and S1P. Data of 4 to 6 independent experiments performed 
in duplicate are shown. ERK1/2 and AKT activation and cell migration assays are detailed in Methods.
Downloaded from http://www.jci.org on June 30, 2015.   http://dx.doi.org/10.1172/JCI67333
research article
4716 The Journal of Clinical Investigation   http://www.jci.org   Volume 123   Number 11   November 2013
Downloaded from http://www.jci.org on June 30, 2015.   http://dx.doi.org/10.1172/JCI67333
research article
 The Journal of Clinical Investigation   http://www.jci.org   Volume 123   Number 11   November 2013 4717
in vessel formation and stability in other pathophysiological set-
tings has not been addressed.
We report herein that GRK2 is a relevant modulator of angio-
genesis during development and tumor formation. GRK2 dosage 
is important in determining how ECs integrate different relevant 
physiological stimuli and to balance TGF-β signaling to down-
stream pathways. Furthermore, ablation of GRK2 compromises 
postnatal angiogenesis and vascular remodeling in the retina 
and vasculogenesis during embryonic development as a result of 
defective vessel maturation, whereas GRK2 downregulation in 
ECs reduces pericyte coverage of tumoral vessels and potentiates 
tumor progression.
Results
GRK2 expression levels modulate the angiogenic response. To test wheth-
er GRK2 could impact the angiogenic process, we analyzed the 
in vivo neovascularization induced by Matrigel plugs mixed with 
the potent angiogenic inducers S1P, VEGF, or FGF2 subcutane-
ously injected in WT or hemizygous Grk2+/– mice (which express 
40%–50% less kinase protein as compared with WT animals). As 
expected, each of these angiogenic factors induced hemoglobin 
accumulation in WT mice, as a readout of the occurrence of func-
tional blood vessels. Interestingly, decreased expression of GRK2 
resulted in marked reduction of hemoglobin content in response 
to either factor (Figure 1A), suggesting an alteration in vessel num-
ber and/or functionality.
We next analyzed whether such impaired angiogenic response 
could be caused by defective EC responsiveness using murine lung 
ECs (MLECs) isolated from WT or Grk2+/– mice. Neither AKT nor 
ERK activation was compromised in response to VEGF (Supple-
mental Figure 1A; supplemental material available online with this 
article; doi:10.1172/JCI67333DS1) or S1P (Figure 1B) in Grk2+/– 
MLECs compared with that in WT cells but was instead modestly 
enhanced at longer times of stimulation (Figure 1B). Consistently, 
no significant changes in cell proliferation were noted between 
WT and Grk2+/– MLECs stimulated with angiogenic factors or with 
serum (Supplemental Figure 1B). As a major effect of S1P in vessel 
formation is to mobilize ECs, the influence of GRK2 levels on S1P-
induced chemotactic motility of MLECs was examined. Reduced 
GRK2 expression markedly enhanced migration toward S1P or 
fibronectin (Figure 1C), and a similar trend was also observed in 
response to VEGF (Supplemental Figure 1C). Both fibronectin- 
and S1P-induced EC migration were abrogated by inhibition of 
the upstream AKT activator PI3K (Figure 1D), suggesting that 
modulation of AKT stimulation by GRK2 levels (see Figure 1B) 
might be crucial for motility in ECs.
Overall, these results suggested that changes in EC proliferation 
or migration were not related to the impaired angiogenic response 
observed in Grk2+/– mice in the Matrigel plug assay. As functional 
vessel formation also requires endothelial tubular organization and 
concomitant pericyte coverage, vascular architecture was analyzed 
in sections of S1P- or FGF2-embedded Matrigel plugs. Capillary-
like structures expressing both CD31 and SMA or NG2 as markers 
of endothelial and mural cells, respectively, were readily observed 
in WT animals (Figure 2A and Supplemental Figure 2A), consis-
tent with the formation of mature vessels, but not in Grk2+/– mice. 
In the later animals, CD31- or NG2-positive cells were distributed 
scatteredly or clustered in anarchic masses, suggestive of aberrant 
endothelial structures lacking mural coverage, despite the fact that 
endothelial and mural Grk2+/– cells infiltrate Matrigel plugs even 
better than those in WT animals (Figure 2A). This is consistent 
with the enhanced migration upon GRK2 downmodulation in 
MLECs (see above) or in isolated VSMCs toward the endothelial-
derived chemoattractant PDGF-BB (Supplemental Figure 1D).
Since no angiogenic phenotype has been described in mice 
with specific GRK2 depletion in VSMCs (15), we reasoned that 
aberrant angiogenesis in global Grk2+/– mice might be caused 
by GRK2-triggered intrinsic defects of ECs. In support of this, 
endothelium-specific downregulation of GRK2 (in endothelium-
specific hemizygous mice) also resulted in an impaired angiogenic 
response in vivo (Figure 2B) and recapitulated vessel deficiency 
with an unstructured cellular network characterized by a sparse 
accumulation of endothelial and mural cells (Supplemental Fig-
ure 2B). An extra endothelium-specific decrease in GRK2 expres-
sion (Tie2Cre-Grk2fl/– animals in Supplemental Figure 2, C and 
D, or Tie2Cre-Grk2fl/fl mice in Figure 2C) further worsened this 
vascular phenotype in Matrigel implants.
These results indicated that altered GRK2 levels in ECs are 
sufficient to compromise key functions required for successful 
angiogenesis. Consistently, we found that the capacity of iso-
lated MLECs to form “well-resolved” tubular networks in vitro 
was dampened by GRK2 downregulation in a dose-dependent 
manner (Figure 2, D and E). It is worth noting that a compensa-
tory increase in the expression levels of other closely related GRK 
isoforms was not detected in MLECs from global GRK2 hemizy-
gous mice (Supplemental Figure 2E). Tube length and tube for-
mation index parameters (see Methods) were inherently impaired 
in Grk2+/– MLECs in low serum conditions (Figure 2D) and also 
in response to angiogenic stimuli (Figure 2E and Supplemental 
Figure 2F), pointing out that GRK2 levels can impact endothelial 
differentiation and remodeling.
TGF-β signaling through ALK1 and ALK5 receptors in ECs is unbal-
anced upon GRK2 downregulation. Tubular morphogenesis requires 
coordination of manifold paracrine and autocrine signaling 
Figure 2
Endothelial GRK2 protein levels regulate vascular morphogenesis. 
(A–C) Angiogenesis in mice with global or endothelial-specific reduc-
tion of GRK2 expression is characterized by a lack of functional ves-
sels, concomitant with the occurrence of aberrant vessel-like structures 
with a poor mural coverage. Sections of FGF2-embeded Matrigel plugs 
excised (A) from WT Grk2+/+ and global Grk2+/– or (C) from Tie2Cre-
Grk2fl/fl mice were analyzed by immunohistochemistry, and the density 
of invasion by either endothelial or mural cells was determined with 
(A) anti-CD31 or anti-NG2 or (C) SMA antibodies, respectively, as 
detailed in Methods. Ratios of CD31-positive cells to total DAPI-stained 
cells in FGF2-stimulated WT Grk2+/+ and Tie2Cre-Grk2fl/fl mice were 
0.22 ± 0.06 and 0.58 ± 0.28, respectively. (B) Endothelial GRK2 down-
modulation is sufficient to impair the functionality of angiogenic ves-
sels. The angiogenic response in WT or Tie2Cre-GRK2 f/+ mice was 
determined as in Figure 1A. Data from 12 animals for each condition 
in 4 independent experiments are shown. (D and E) ECs with deficient 
GRK2 expression are less competent to form capillary-like networks in 
vitro. MLECs from WT (Grk2+/+), global hemizygous (Grk2+/–), or endo-
thelial-specific (Tie2Cre-Grk2fl/fl) GRK2 knockout mice were seeded 
on Matrigel-coated wells in the presence of (D) 1% FCS or (E) 5% 
FCS. Photographs were taken after 16 to 18 hours in culture (original 
magnification, ×5), and formation of tubular networks was quantified 
as described in Methods. Data were obtained from 2 to 3 indepen-
dent assays performed in duplicate. Scale bar: 100 μm (A); 25 μm 
(C, Tie2Cre-Grk2fl/fl and vehicle-treated Grk2+/+); 50 μm (C, FGF2-treat-
ed Grk2+/+); 500 μm (D and E).
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factors. TGF-β appears to be central to this process, as diverse 
angiogenic stimuli such angiopoietin 1 or PDGF control its 
production and secretion (17), and TGF-β itself upregulates key 
angiogenic modulators such as S1P and FGF2 (18), VEGF (19), 
or PDGF-BB (20) in ECs, which altogether cooperate to build 
up vascular networks (5). Since reciprocal regulation of TGF-β 
signaling and GRK2 expression has been reported in other cells 
types (11, 21), we analyzed whether GRK2 downregulation 
could alter TGF-β–dependent modulation of EC differentiation. 
Although contradictory TGF-β activities on tube formation 
have been reported (5), in general, low doses of TGF-β seem to 
promote a robust and better-organized capillary network, while 
high concentrations (5–10 ng/ml) restrict sprouting, prolifera-
tion, and tube-like aggregation (18, 22). In response to S1P, an 
abundant angiogenic component that accounts for the serum 
effects on EC proliferation/migration (23), the cord-like pattern 
of WT MLECs displayed similar characteristics and tube forma-
tion indexes (Figure 3A) as those promoted by complete serum 
(see Figure 2E), while the additional presence of increasing doses 
of TGF-β did not impair formation of well-developed intercon-
necting tubes (Figure 3A). In contrast, tube formation index in 
Grk2+/– MLECs was markedly reduced with the higher concentra-
tion of TGF-β assessed, suggesting that a normal complement of 
GRK2 would be needed to counterbalance the inhibitory effects 
of TGF-β signaling in angiogenesis. In keeping with this, Grk2+/– 
MLECs were more sensitive than WT cells to the antiproliferative 
effects of high doses of TGF-β (Supplemental Figure 3A).
It has been suggested that ALK1 activation by low concentrations 
of TGF-β overcomes ALK5-mediated block of proliferation/migra-
tion (favoring the angiogenic activation phase). However, at high 
concentrations of TGF-β, ALK5 signaling predominates, thereby 
contributing to ulterior angiogenic resolution phases (4, 24). 
Interestingly, we found that specific TGF-β–dependent activa-
tion of ALK1 (monitored by phosphorylation of Smad1/5) was 
significantly attenuated in Grk2+/– MLECs compared with that 
in their WT counterparts (Figure 3B). In marked contrast, ALK5-
mediated phosphorylation of Smad2/3 was clearly upregulated in 
cells with lower GRK2 levels, suggesting that this protein might 
be instrumental in keeping the balanced TGF-β signaling required 
for proper angiogenesis.
To gain further insight in the molecular mechanisms by which 
GRK2 levels modulate the highly interconnected ALK1/ALK5 path-
ways, we used specific modulators of such signaling routes. The 
enhanced stimulation of ALK5-dependent Smad2/3 phosphoryla-
tion observed in Grk2+/– MLECs was compatible with the previously 
reported direct inhibitory effect of GRK2 on Smad2/3 activity (11). 
In agreement with such a potential mechanism, Grk2+/– MLECs 
were less sensitive than their WT counterparts to inhibition of 
Smad2/3 activation by the specific Smad3 inhibitor SIS3 (Supple-
mental Figure 3B), whereas signaling in both cell types was similar-
ly blocked by the upstream ALK5 inhibitor A8301 (Supplemental 
Figure 3B). Interestingly, in WT and Grk2+/– MLECs, the presence 
of the SIS3 inhibitor did not affect TGF-β–mediated stimulation 
of the ALK1-Smad1/5/8 branch (Supplemental Figure 3C). This 
result excludes a potential negative crosstalk from ALK5 to ALK1 
at the Smad level and suggests the occurrence of additional mecha-
nisms of GRK2 modulation. Consistent with this notion, phos-
phorylation of Smad1/5/8 in response to the specific ALK1 ago-
nist BMP9 was also clearly hampered in Grk2+/– MLECs compared 
with that in WT MLECs (Figure 3C). Overall, these data suggest 
that GRK2 levels would modulate TGF-β signals in ECs by both 
inhibiting ALK5 signaling at the level of Smad2/3 and by positively 
contributing to the activation of the ALK1 route. The fact that we 
could not observe direct phosphorylation of ALK5 or ALK1 recep-
tors by GRK2 (data not shown) further supports the notion that 
the targets of modulation lie downstream of the receptors.
GRK2 expression modulates the secretion profile of endothelial autocrine 
and paracrine factors. Tight control of PDGF-BB expression in ECs is 
important for proper mural cell coverage (9, 25) and this factor is 
upregulated by ALK5-Smad2/3 activation (20). Interestingly, basal 
secretion of PDGF-BB in quiescent ECs was circa 3- to 4-fold high-
er in Grk2+/– MLECs compared with that in WT cells (Figure 3D), 
whereas the former failed to further increase secretion of PDGF-BB 
in response to VEGF or TGF-β as occurred in WT cells (Figure 3D). 
The basal secretion of PDGF-BB was markedly diminished in WT 
MLECs treated with the specific ALK5 inhibitor A8301 but not as 
efficiently in Grk2+/– MLECs (Figure 3E), consistent with ALK1/
ALK5 signaling imbalance upon GRK2 deficiency. In addition, 
the secretion pattern of antiangiogenic-to-proangiogenic–related 
factors was also unbalanced in quiescent Grk2+/– MLECs, with 
diminished levels of angiostatic factors and molecules involved in 
the maturation phases of angiogenesis, such as IL-13, PF4, IP-10, 
or TSP1 (Supplemental Figure 3D). Consistent with the fact that 
PDGF-BB expression during angiogenesis seems to be restricted 
to immature endothelium (26), Grk2+/– MLECs formed stable, 
mature vascular structures less proficiently, as also suggested by 
the increased permeability of their endothelial monolayers com-
pared with those of WT cells (Supplemental Figure 3E). Thus, 
improper/untimely endothelial secretion of PDGF upon GRK2 
downregulation might determine the defective attachment of 
mural cells to endothelial angiogenic structures observed in sys-
temic or endothelium-specific GRK2 hemizygous mice.
Endothelial downregulation of GRK2 levels leads to an altered pattern 
of vessel growth and maturation in the postnatal mouse retina. In order 
to shed light on the functional impact of altered GRK2 levels in 
ECs on the angiogenic process, we used the mouse retina model, 
which has been extensively used to investigate both physi-
Figure 3
Effect of GRK2 downregulation on TGF-β1 endothelial signaling.  
(A) ECs with reduced expression of GRK2 are more sensitive to 
dose-dependent inhibitory effects of TGF-β1 on tube network forma-
tion. In vitro tube formation was monitored in the presence of 1 μM 
S1P supplemented with or without 0.5 or 5 ng/ml TGF-β1 and quanti-
fied as in Figure 2, D and E. Data from 3 independent assays per-
formed in duplicate are shown. Scale bar: 500 μm. (B and C) Proper 
signaling of Smads downstream of ALK1 and ALK5 receptor acti-
vation depends on GRK2 expression. (B) Grk2+/– MLECs display 
enhanced TGF-β1–triggered activation of Smad2/3 paralleled by a 
decrease in Smad1/5/8 stimulation. The lanes were run on the same 
gel but, where indicated by the black vertical line, were noncontigu-
ous. (C) BMP9-induced activation of Smad1/5/8 via ALK1 is reduced 
in Grk2+/– MLECs. (D) Both basal and angiogenic factor–induced 
PDGF-BB secretion are altered in Grk2+/– MLECs. Serum-starved 
cells were incubated for 48 hours in 1% FCS supplemented with or 
without 50 ng/ml VEGF or 5 ng/ml TGF-β1, and PDGF-BB was deter-
mined in the cell-conditioned media as described in Methods. (E) The 
production of PDGF-BB in Grk2+/– MLECs is less sensitive to ALK5 
signaling inhibitors. Media of cells treated with 5 ng/ml TGF-β1 for 
48 hours in the presence or absence of the ALK5 inhibitor A8301 (5 μM) 
was processed for PDGF-BB quantification. In B–E data from 3–4 
independent experiments are shown.
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Figure 4
Loss of endothelial GRK2 impairs developmental outgrowth 
and maturation of the retinal vasculature. (A and B) Expan-
sion of the primary vascular plexus and endothelial filopo-
dia was reduced in the absence of GRK2. (A) Whole-mount 
P9 retinas from WT (Grk2fl/fl; n = 5) or Tie2Cre-Grk2fl/fl 
(n = 5) pups were stained with endothelial FITC-ILB4 
marker. The ILB4-positive area was quantified in the entire 
retinal surface (low magnification) or in proximal regions 
of the vascular plexus (high magnification) (WT, n = 15; 
mutant, n = 12) as detailed in Methods. (B) Filopodia of 
tip cells were counted in high-power fields of 5 WT retinas 
(n = 17) and 6 Tie2Cre-Grk2fl/fl retinas (n = 18). (C and D) 
Delayed recruitment of pericytes to retinal ECs and per-
turbed cell-cell interactions in mutant mice. Whole-mount 
(C) P9 and (D) P14 retinas of WT (n = 5) and Tie2Cre-
Grk2fl/fl (n = 5) mice were double stained with ILB4-FITC 
and anti-NG2 antibodies, and the corresponding positive 
areas were quantified (n = 14 and n = 11 images, respec-
tively) as detailed in Methods. (C) Pericyte coverage was 
expressed as the percentage fraction of colocalizing peri-
cyte- and endothelial-positive areas. (D) Abnormal associa-
tion of pericytes with endothelial capillaries in the primary 
vascular plexus of P14 Tie2Cre-Grk2fl/fl retinas. Some peri-
cytes remain dissociated from ECs and make irregular con-
nections between endothelial capillaries (zoomed images). 
High-magnification fields (n = 12 from retinas of 5 Grk2fl/fl; 
n = 20 from retinas of 5 Tie2Cre-Grk2fl/fl) were inspected. m, 
macrophages. Scale bar: 100 μm (A, C, and D); 25 μm (B).
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ologic and pathologic angiogenesis (27). We observed defec-
tive vessel outgrowth in the P9 retinas from Tie2Cre-Grk2fl/fl 
mice, characterized by reduced vascular density and delayed 
radial expansion of the superficial vascular plexus (Figure 4A). 
A similar trend was noted upon endothelial marker quantifica-
tion in high-power fields of central areas of the capillary plexus 
(Figure 4A). Moreover, the number of loops in the retinal vas-
culature of Tie2Cre-Grk2fl/fl mice was clearly reduced compared 
with that of WT animals (Supplemental Figure 4A), pointing 
to a deficient branching activity and consistent with a reduced 
vascular density in mutant P9 retinas. Consistently, sprouting 
activity (measured by the number of filopodia per field) was sig-
nificantly impaired at the vascular front in P9 retinas depleted of 
endothelial GRK2 (Figure 4B). In addition, both the lower pres-
ence of NG2-positive cells in the retinas of P9 Tie2Cre-Grk2fl/fl 
pups (Supplemental Figure 4B) and the reduced extent of 
endothelial/pericyte surface colocalization compared with that 
in WT animals (Figure 4C) suggested marked defects in pericyte 
recruitment to retinal vessels and inadequate endothelial cover-
age upon GRK2 downregulation.
Figure 5
Abnormal vascular network formation and morphology in global GRK2 knockout embryos. (A–D) Vascular expression pattern of GRK2 in WT 
embryos. Triple immunostaining of (A) GRK2 and (B) endothelial and (C) smooth muscle markers in an E10.5 Grk2+/+ embryo. GRK2 is expressed 
in cells around the aorta (ao), colocalizing with SMA (arrowheads). Most aortic endothelium is GRK2 negative (blue arrows), while GRK2 colocal-
izes with PECAM1 in some small vessels (white arrows). (E) A small GRK2-positive vessel emerging from the aorta toward the lung bud (lb) in an 
E11.5 embryo (arrows). By this stage, colocalization of GRK2 with SMA is more prominent in the aortic media. (F and G) GRK2-positive ECs in 
small vessels of the perineural plexus around the (F) neural tube (nt) and (G) lung bud from an E11.5 embryo. Note GRK2/SMA colocalization in 
the myotome (myo). (H–J) Vascular phenotype of E10.5 GRK2-null (Grk2–/–) embryos. (H) In contrast to normal aortic wall architecture in the WT 
embryo, (I and J) the wall of large- and medium-sized vessels of the GRK2-null embryos was constituted of only PECAM-positive ECs, with few 
SMA-positive cells loosely connected to the endothelium (arrows). (K and L) Lack of angiogenic growth of vessels (arrows) within the neural tube 
of (L) GRK2-null compared with (K) WT embryos. Note the disorganized vessel wall of the perineural plexus in the mutant embryo. (M) Whole-
mount view of E10.5 yolk sacs isolated from Grk2+/+, Grk2+/–, and Grk2–/– embryos. Large blood vessels are completely absent in Grk2–/– mice. 
Scale bar: 25 μm (A–J); 50 μm (K and L).
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Interestingly, in the P14 retinas, radial expansion of capillary plex-
us and pericyte/endothelial ratios appeared to be similar in Tie2Cre-
Grk2fl/fl retinas compared with that in WT animals (Supplemental 
Figure 4, C and D), suggesting that defective vascular growth was 
solved over time in the mutant animals. However, a careful analysis 
revealed that the full maturation of retinal vasculature was still per-
turbed in the absence of endothelial GRK2 expression, as vascular 
remodeling was deficient and/or delayed. In the mouse retina, vas-
culature is remodeled from an initially exuberant interconnected 
vessel meshwork into a simplified architecture that facilitates effi-
cient blood flow (28). Regression of capillaries results in the forma-
tion of capillary-free zones around arteries with a marked reduction 
in vascular density. Notably, such reduction was not achieved in 
Tie2Cre-Grk2fl/fl retinas at P14, when pruning of the primary plexus 
was almost completed in control animals (ref. 29 and Supplemen-
tal Figure 4C). Moreover, vascular loops were irregularly formed in 
Tie2Cre-Grk2fl/fl mice compared with those in WT mice, as shown 
by the higher branching detected in P14 Tie2Cre-Grk2fl/fl retinas 
(Supplemental Figure 4C). All these alterations were suggestive of an 
impaired functional interaction between ECs and pericytes. In keep-
ing with this, P14 retinas of Tie2Cre-Grk2fl/fl mice displayed pericytes 
that were abnormally associated with endothelial vessels, connecting 
adjacent vessels without an underlying endothelial track (Figure 4D).
Overall, our data suggested that endothelial GRK2 was a key 
modulator of vessel outgrowth in the mouse retina and that its 
downmodulation impaired the establishment of proper function-
al EC-pericyte interactions, resulting in impaired timing of vascu-
lar remodeling and selective vessel regression.
GRK2 deficiency leads to abnormal vessel formation in the mouse 
embryo, with decreased recruitment of vascular pericytes. To further 
substantiate that GRK2 expression was critical for vascular func-
tionality in physiological contexts, we analyzed the development 
of embryonic vasculature in the absence of GRK2. We first inves-
tigated the expression pattern of GRK2 in vessels of E9.5–E11.5 
WT mouse embryos using different anti-GRK2 antibodies. Peri-
vascular cells were consistently positive for GRK2 staining, and the 
GRK2 label colocalized with smooth muscle cell markers in large 
vessels such as the aorta (Figure 5, A and D, and Supplemental Fig-
ure 6A) more prominently by E11.5 (Figure 5E). GRK2 expression 
in the endothelium was more dynamical, with widespread stain-
ing in small-diameter vessels, in vessels emerging from the aorta, 
or in the perineural plexus (Figure 5, A–G, white arrows), whereas 
large vessels displayed patchy immunoreactivity, with a number of 
ECs being negative for GRK2 expression (Figure 5D, blue arrows, 
and Supplemental Figure 6A). This suggests that GRK2 expres-
sion would be upregulated in the endothelium undergoing normal 
physiological angiogenesis.
Interestingly, vasculature was markedly altered in systemic Grk2–/– 
mouse embryos compared with that in WT embryos. At E9.5 and 
E10.5, gross malformations were observed, along with clear defects 
in perivascular cell recruitment, which gave rise to large vessels 
such as the aorta being lined essentially only by ECs. Perivascu-
lar SMA-positive immunoreactive cells were scarce and usually 
showed little contact with ECs (Figure 5, H–J, and Supplemental 
Figure 5, E–H). Purely angiogenic vessel growth was also impaired, 
as shown by the lack of vascular invasion of the neuroectoderm 
in the knockout embryos (Figure 5, K and L, and Supplemental 
Figure 5, A–D). In the Grk2–/– embryos, vessels of the perineural 
plexus were markedly dilated around the neural tube (Figure 5L) 
and around the encephalon (Supplemental Figure 5, C and D). 
Other vessels in Grk2–/– animals adopted irregular shapes, leading 
to marked asymmetry in the paired aorta (Supplemental Figure 5, 
G–J) and to abnormal vascularization in the limbs (Supplemental 
Figure 5, K and L). Some large vessels even displayed discontinui-
ties in the endothelial layer, which could explain some occasional 
hemorrhages found in GRK2-deficient embryos (Supplemental 
Figure 5J and Supplemental Figure 6B). Moreover, expansion of the 
primitive capillary plexus of yolk sacs was severely compromised 
in Grk2–/– embryos (Figure 5M and Supplemental Figure 6C). 
In parallel to such generalized defects in both capillaries and large 
vessels, Grk2–/– embryos showed noticeable mesenchymal apopto-
sis in different regions at E10.5 (Supplemental Figure 6D).
Remarkably, embryos with selective genetic ablation of GRK2 
in the endothelium (Tie2CRE-Grk2fl/fl embryos) also displayed 
vascular abnormalities at E10.5 to E11.5, consisting of poor and 
sparse mural coverage of large vessels. Contrary to that in WT 
mice, endothelia of the aortas did not show appropriate cover-
ing by WT SMA-positive cells (Figure 6, A and B). Some degree 
of interindividual variability in the extent of mural coverage was 
observed in Tie2-targeted GRK2 knockout embryos, which might 
reflect an incomplete Cre-dependent inactivation of floxed GRK2 
alleles, as inferred by a patchy staining of endothelial GRK2 in 
knockout embryos (Figure 6, C and D). Similar to systemic Grk2–/– 
animals, we observed that endothelial-restricted GRK2 knockout 
mice displayed scarce vascularization of the neuroectoderm com-
pared with that in WT littermates (Figure 6, E and F), dilated ves-
sels with irregular shapes in hindbrain and limbs (Figure 6, E–H), 
and asymmetry in the paired aortas (Figure 6I). All these find-
ings were consistent with altered vessel maturation and impaired 
recruitment of mural cells taking place in this experimental 
model. Interestingly, despite their blood vessels seeming to be 
similarly malformed and immature, Tie2Cre-Grk2fl/fl embryos did 
not show apoptosis to the extent observed in global GRK2 knock-
out embryos, suggesting that extravascular defects would contrib-
ute to such process in the latter animals. Consistently, vascular 
anomalies in endothelium-specific GRK2 knockout embryos did 
not impede their development and postnatal survival. However, 
Tie2Cre-Grk2fl/fl mice showed vascular malformations at adult-
hood (Figure 6, J–S). In some animals the microvasculature of 
the heart displayed probable microhemorrhages, as suggested by 
the intratissular blood accumulation not surrounded by endo-
thelium (Figure 6Q). This is indicated by the lack of PECAM and 
laminin staining (Figure 6, Q and R). Blood vessels in liver were 
also affected, showing increased capillary size, reduced mural 
coverage, and disorganized vascular pattern (Figure 6, O and P). 
The above results clearly demonstrated that endothelial GRK2 is 
pivotal for the control of vascular maturation by influencing the 
extent of mural cell recruitment and endothelial coverage.
Impaired mural cell recruitment and increased size of tumor vessels cor-
relates with tumor growth upon GRK2 downregulation in vivo. Tumor 
microvasculature is usually highly angiogenic and leaky, with 
enlarged and dilated vessels of irregular contours lined by imma-
ture walls as a result of pericyte loss and diminished deposition of 
basement membrane (30). Since many of the hallmarks of tumor 
vessels were recapitulated upon ablation or downregulation of 
endothelial GRK2 levels, we investigated whether the pattern of 
vessel formation in tumors and tumor growth was influenced by 
the extent of GRK2 expression in ECs. B16F10 melanoma cells were 
implanted subcutaneously in global hemizygous GRK2 mice with 
different levels of endothelial GRK2 (Grk2+/– mice retaining 50% of 
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GRK2 protein at endothelium or Tie2Cre-Grk2fl/– mice, expressing 
approximately 25% of this protein; Supplemental Figure 2D), and 
subsequent evolution of tumors was compared with that in WT 
animals. The “quality” of the tumor vessels driven by B16F10 mela-
noma cells was particularly poor in Grk2+/– mice, causing irregu-
lar blood perfusion (Supplemental Figure 7A). We observed that 
tumors grown in mice with lower endothelial levels of GRK2 consis-
tently reached larger sizes in a dose-dependent manner (Figure 7A). 
Staining of tumor sections with EC markers demonstrated an 
increase in the proportion of large and dilated vessels (Figure 7, 
B and C) in tumors grown in mice displaying reduced GRK2 protein 
at endothelium. Moreover, tumors implanted into Tie2Cre-Grk2fl/– 
mice contained vessels with a substantial reduction in colocaliza-
tion of SMA-positive cells (Figure 7D). Quantification of mural cell 
coverage revealed circa 90% reduction in these animals compared 
with that in WT animals (Figure 7E). We investigated whether such 
deficient pericyte-endothelial attachment would favor extravasa-
tion of immune cells such as macrophages, which positively con-
tribute to tumor growth (31). Interestingly, we observed a higher 
infiltration of macrophages in tumors grown in Tie2Cre-Grk2fl/– 
mice (Figure 7F). Thus, we investigated in more detail this process 
and its potential contribution to enhanced tumor growth in endo-
thelium-deficient GRK2 mice. The conditioned medium of MLECs 
isolated from Tie2Cre-Grk2fl/fl animals displayed an enhanced abil-
ity to promote macrophage migration compared with that of WT 
MLECs (Figure 8A), likely related to the increased basal secretion 
of CXCL12 (Supplemental Figure 7B) and of other macrophage 
regulatory and chemoattractant factors, such as GM-CSF, KC, or 
Figure 6
Specific downregulation of endothelial GRK2 expression causes vascular malformations during embryonic development and at adulthood. (A–D) 
Endothelial-specific ablation of GRK2 leads to a delayed formation of the aortic media. GRK2 immunoreactivity is reduced in endothelium of 
E11.5 embryos (arrows in D), while GRK2 staining of nervous ganglia adjacent to the aorta is unaffected. The aortic endothelium shows defective 
covering of SMA-positive cells (arrows in B) in mutant animals. (E–I) Vascular defects in E10.5 embryos upon specific ablation of endothelial 
GRK2. Angiogenesis of the hindbrain is delayed in Tie2Cre-Grk2fl/fl embryos. PECAM1-positive vessels can be seen within the neuroectoderm of 
control embryos (arrowhead in E), but they are scarce or absent in Tie2Cre-Grk2fl/fl embryos (arrows in E–I indicate representative vessels). Ves-
sels of the perineural plexus (arrows in E) and of the limb bud (arrows in H) are dilated in the mutant embryo as compared with the WT (F and G, 
respectively). The paired aorta from this Tie2Cre-Grk2fl/fl embryo also shows a reduced left branch (arrow in I), similar to that of the systemic 
mutant (see Supplemental Figure 5). (J–S) Adult mice with endothelial-specific ablation of GRK2 show disorganization and dilatation of small 
vessels and capillaries in the liver (arrows in O and P). GRK2 staining is strongly reduced in the cardiac endocardium (compare to arrows in 
J and N) and coronary endothelium of Tie2Cre-Grk2fl/fl mice. Extravascular blood accumulations without PECAM1-positive endothelium covering 
(arrows in Q) and lacking SMA and laminin immunoreactivity (arrows in R and S) suggests microhemorrhages. A normal coronary vessel is shown 
(arrowhead in R). Scale bar: 25 μm (C–F); 50 μm (A, B, G–I, K, L, O, and P); 100 μm (J, M, N, and Q–S).
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Factor-III (Supplemental Figure 7C), detected in ECs upon GRK2 
downregulation. On the other hand, in line with data shown in 
Figure 7F, B16F10-derived tumors grown in Tie2Cre-Grk2fl/fl mice 
showed a marked increase of intratumoral hypoxia (indicative of 
altered vascularization) and of the tumor-associated macrophage-
derived factor adrenomedullin (Figure 8B). Moreover, consistent 
with an important role for enhanced macrophage infiltration in 
this experimental model, tumor growth was favored by the presence 
of extra injected M2-polarized RAW267.4 macrophages in both WT 
mice and mice deficient of GRK2 in endothelia (Figure 8, C and D), 
and depletion of endogenous macrophages upon clodronate treat-
ment abrogated the marked differences in tumor growth observed 
Figure 7
Endothelial GRK2 levels influence tumor growth by altering pericyte recruitment and tumor microvasculature. (A) Tumors implanted in mice with 
reduced endothelial expression of GRK2 exhibit higher growth rates. B16F10 melanoma cells were subcutaneously injected in mice and tumor 
size was monitored as described in Methods (n = 3–4 animals for each condition in 3 independent experiments). P values indicated in compari-
sons between WT and hemizygous mice and between hemizygous and Tie2Cre-Grk2fl/– mice. (B and C) Higher occurrence of large and dilated 
vessels in tumors grown in Tie2Cre-Grk2fl/– mice. Tumor sections were stained with the endothelial biotinylated ILB4 marker and hematoxylin 
counterstained. Vessel size was calculated as detailed in Methods. Distribution of vessel diameter in each condition is shown in C. (D and E) 
Reduced pericyte recruitment in tumors implanted in Tie2Cre-Grk2fl/– mice. Sections of tumors were (D) stained with biotinylated ILB4 and anti-
SMA antibodies or (E) double stained with fluorescein-ILB4 and anti-SMA antibodies to quantify the mural coverage as described in Methods. 
Data were expressed as a percentage of the total ILB4-positive area. (F) Tumors grown in Tie2Cre-Grk2fl/– mice show increased macrophage 
density compared to those implanted in WT mice. The number of F4/80-positive cells in different sections covering the whole tumor mass is 
shown. Two distinct specimens were analyzed for each condition. Scale bar: 100 μm.
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B16F10 melanoma and human breast cancer cell lines MCF7 
and Hs578T, but not normal mammary 184B5 cells, signifi-
cantly reduced the amount of GRK2 protein expressed in WT 
MLECs after 24 hours of coculture (Figure 9A). Such downregu-
lation was even more pronounced and rapid in Grk2+/– MLECs. 
Analysis of GRK2 levels in gene expression databases for ECs iso-
lated from normal resting, regenerating, and malignant tissues 
or contexts (32) indicated that normal ECs from regenerating 
between WT and Tie2Cre-Grk2fl/fl mice in control conditions 
(Figure 8, E and F), strongly suggesting that the enhanced recruit-
ment of macrophages occurring upon endothelial GRK2 down-
modulation played a relevant role in fueling tumor development.
Tumor-derived factors reduce the expression of GRK2 in the endotheli-
um of tumor microvasculature. We reasoned that tumor cells might 
harness the role of GRK2 in vessel stability by actively promot-
ing its downregulation in the endothelium. Remarkably, both 
Figure 8
Absence of endothelial GRK2 expres-
sion enhances monocyte migration in 
vitro and promotes tumor growth in a 
macrophage-dependent manner. (A) 
Enhanced RAW267.4 macrophage 
recruitment in response to condi-
tioned media from ECs lacking GRK2. 
48-hour-conditioned media of MLECs 
from WT Grk2+/+ or Tie2Cre-Grk2fl/fl 
mice were used as chemoattractant 
in Transwell migration assays (data 
from 3 to 4 independent experiments 
performed in duplicate). (B) Lack 
of endothelial GRK2 contributes to 
enhance intratumoral hypoxia and 
adrenomedullin expression. B16F10 
melanoma cells were subcutaneously 
injected in mice, and tumors were 
removed 17 days after and stained 
with the anti-pimonidazole–based 
adducts FITC-Mab1 antibody for 
detection of hypoxia or anti-adreno-
medullin antibody, as detailed in Meth-
ods, and hematoxylin counterstained. 
Scale bar: 500 μm (hypoxia, first and 
third images); 50 μm (hypoxia, second 
and fourth images); 100 μm (adre-
nomedullin). (C and D) M2-polar-
ized macrophages enhance tumor 
growth. B16F10 melanoma cells 
were subcutaneously injected in WT 
or Tie2Cre-Grk2fl/fl mice in the pres-
ence or absence of IL4-pretreated 
RAW267.4 cells as described in Meth-
ods. Sizes of tumors implanted in WT 
mice equal those in Tie2Cre-Grk2fl/fl 
mice in control conditions when tumor 
cells in the formers are implemented 
with macrophages. (E and F) Effects 
of clodronate-promoted depletion 
of macrophages on tumor growth. 
Tumor-bearing mice were treated with 
control liposomes (encapsome) or 
clodronate-encapsulated liposomes 
by intraperitoneal injection starting 
24 hours before tumor cell inocula-
tion, followed by treatments every 
4 days. Macrophages are involved 
in the higher growth of tumor cells 
implanted in Tie2Cre-Grk2fl/fl mice 
compared to WT animals, as such 
differential growth is abrogated in clo-
dronate-treated Tie2Cre-Grk2fl/fl mice. 
Five to eight animals were analyzed 
for each condition.
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vessels of different human breast cancer samples (Figure 9, B–K). 
GRK2 staining was notable in vessels of normal breast tissue 
and of benign lesions such as adenosis or fibroadenoma. The 
distribution and the intensity of vascular GRK2 staining were 
similar in all normal and benign breast tissues examined, show-
ing a high proportion of vessels (>80%) with a moderate/intense 
signal for GRK2 (Figure 9, B–K). In marked contrast, approxi-
mately 60% of vessels of different breast carcinoma tumors 
mouse liver upregulate GRK2 expression compared with resting 
liver ECs (Supplemental Figure 8A), whereas activated human 
microvascular ECs cocultured with human colorectal cancer 
LS180 cells in the presence of blood components displayed 
GRK2 downregulation compared with quiescent ECs (Supple-
mental Figure 8B) (33). As such an experimental setting mim-
ics the hematogenous microenvironment of tumors caused by 
a leaky vasculature, we analyzed GRK2 expression in tumoral 
Figure 9
Tumor-derived factors reduce the expression of GRK2 in the endothelium of tumor microvasculature. (A) GRK2 downregulation in MLECs 
exposed to factors secreted by tumoral but not by nontransformed cell lines. WT or GRK2+/– derived MLECs were cocultured with the different 
malignant or normal mammary (184B5) cell lines as described in Methods (n = 3–4 independent experiments). (B–J) GRK2 expression is mark-
edly decreased in tumor EC cells of breast cancer patients. Immunohistochemical staining of normal and different benign and malignant lesions 
of the mammary gland reveals that vessels from nontumoral tissues (B–G) show a noticeable signal for GRK2 at the endothelial layer, while 
tumoral vessels of breast carcinomas (H–J) display lower or even undetectable GRK2 levels. Normal vessels at the tumor margin retain GRK2 
staining. Blood vessels were identified by the presence of blood cells and by anatomic features. Representative vessels are indicated with arrows. 
(B–D) Normal breast, (E) mild hyperplasia, (F) fibroadenoma, (G) adenosis, and (H–J) breast carcinomas samples were analyzed. T, tumoral 
area; NT, nontumoral area. (K) Relative vessel immunoreactivity was evaluated by two investigators in a blinded fashion and classified as strong, 
moderate, or faint/absent GRK2-expressing vessels. The percentage ratio of each vessel group to total vessels analyzed in each breast tissue 
condition was represented. The number of vessels analyzed was 73 in 7 cases of normal breast tissue, 139 in 14 cases of benign lesions, and 
138 in 35 patients of breast carcinoma. P values compare normal cells or normal breast tissues. Scale bar: 20 μm.
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the normal course of the activation phase of angiogenesis but also 
for the resolution phase involving vessel coverage by VSMCs/peri-
cytes and vascular stabilization.
GRK2 as a new modulator of TGF-β signaling through ALK1 and ALK5. 
The TGF-β signaling axis is central to the proper integration of 
angiogenic activation and resolution processes (4, 5, 24). Cellu-
lar responses triggered by TGF-β1 in ECs are complex, contrib-
uting positively or negatively to endothelium activation in a con-
text-dependent manner. Such duality might be explained by the 
coexistence of two oppositely acting receptors in ECs, ALK1 and 
ALK5, and their functional cross-modulation (24, 38). We found 
that MLECs from Grk2+/– mice display enhanced Alk5-Smad2/3 
and decreased Alk1-Smad5/8 signaling compared with WT cells 
and that they are more sensitive than WT cells to TGF-β–medi-
ated antiproliferative and anti-tube formation signals at doses 
preferentially targeting ALK5 receptors. The fact that Grk2+/– 
MLECs display an activated phenotype in a signaling context of 
ALK1-Smad5/8 downregulation and fail to assemble mature ves-
sels supports that ALK1 could be also relevant in processes related 
to angiogenic resolution as differentiation or mural recruitment 
(39). Our data suggest that GRK2 levels would alter the balance 
between ALK1/ALK5 pathways in several ways. First, GRK2 would 
inhibit the ALK5 pathway at the level of Smad2/3, consistent with 
the previously reported direct, kinase activity–dependent modula-
tion of this factor by GRK2 in hepatic cells (11). In addition, our 
results indicate that GRK2 positively contributes to the activation 
of the ALK1 route downstream of the receptor. It is tempting to 
suggest that GRK2 downmodulation decreased direct inhibition 
of Smad2/3 and decreased ALK1 signaling–mediated lateral inhi-
bition of the ALK5 pathway (24) would contribute to the observed 
unbalance in TGF-β signaling toward the ALK5 branch.
In sum, we suggest that GRK2 levels can function as a rheostat of 
ALK5 and ALK1 receptor signaling pathways in angiogenesis and 
that alterations in GRK2 activity/levels would disturb signaling 
from TGF-β (and therefore its downstream cross-talk with other 
angiogenic factors), leading to compromised vascular formation.
Reduced GRK2 expression in endothelium leads to an altered pattern of 
vessel growth and maturation in the postnatal mouse retina and to severe 
embryonic vascular malformations. Our results clearly demonstrate a 
key physiological role of GRK2 as a modulator of vessel outgrowth 
in the postnatal mouse retina and in the developing vasculature. 
In the widely used mouse retina angiogenesis experimental model, 
Tie2Cre-Grk2fl/fl animals display clear alterations in the vascular 
density and sprouting activity at P9 as well as impaired timing 
of vascular remodeling at P14 that results in altered vessel archi-
tecture. Impaired filopodia formation and sprouting of retinal 
ECs in Tie2Cre-Grk2fl/fl mice might be related to intrinsic defects 
in their ability to build up tubular morphogenesis (Figure 2, 
D and E, and Supplemental Figure 2F) and to the restrictive effect 
of the ALK5-Smad2/3 signaling branch on sprouting (40), which 
would be strengthened by GRK2 downmodulation. Key to vascu-
lar remodeling is the selective branch regression, or pruning, and 
the stabilization of the remaining vessels, being both processes 
dependent on proper pericyte/EC interactions (29, 28, 41). Thus, 
perturbation of endogenous PDFG-BB gradients by intraocular 
injection of PDGF-BB during vascular remodeling (at P10) results 
in the formation of aberrant endothelial-pericyte interactions sim-
ilar to those observed in P14 retinas of Tie2Cre-Grk2fl/fl mice and 
leads to altered vascular remodeling (29). It is tempting to suggest 
that increased secretion of mural cell attractants, such as PDGF 
displayed only weak signal or no signal for GRK2, and a focal 
pattern of GRK2 staining lining positive vessels was frequently 
observed. Interestingly, lack of GRK2 staining is predominantly 
associated with intratumoral vessels, while vessels in the normal 
tissue surrounding the tumor core are clearly immunoreactive 
for GRK2 (Figure 9, B–K). In addition to the vessel-like pattern 
of GRK2 staining, GRK2 expression was detected in the normal 
epithelial layer of mammary ducts and in the tumor cells them-
selves, albeit at variable levels (Figure 9, B–K).
Discussion
We demonstrate herein that GRK2 plays a crucial role in physi-
ological and tumoral angiogenesis. First, our results indicate that 
GRK2 is involved in counterbalancing the action of different 
angiogenic growth factors responsible for the activation of ECs. 
Such an activation phase involves the orchestration of migra-
tory and proliferative responses by 2 different types of ECs (tip 
and stalk cells) found at angiogenic sprouts. Tip cells are highly 
motile ECs that respond to attractive and repulsive cues, whereas 
stalk cells proliferate and facilitate tube lumen formation (1). We 
found that GRK2 downregulation in MLECs causes enhanced sig-
naling to ERK and AKT cascades in response to S1P and VEGF, 
leading to increased migration. In addition, Grk2+/– MLECs also 
secrete more PDGF-BB, which is a distinctive hallmark of motile 
tip cells (26). Noteworthily, the impact of GRK2 levels in EC 
migration in response to S1P opposes that described in epithelial 
cells and fibroblasts (34), thus strengthening the concept that the 
effects of GRK2 on cell migration would depend on the precise 
stimuli or cell type considered (35). The influence of environmen-
tal cues on the role of GRK2 in migration might be particularly 
relevant during retinal vascular development. Thus, despite GRK2 
downmodulation enhances in vitro migration of ECs toward 
fibronectin and proliferation is not impaired, radial expansion of 
retinal vasculature in mutant mice is reduced. Tip cells produce 
numerous filopodia that help to sense and respond to guidance 
cues during migration. These cytoskeletal protrusions closely 
align to the fibronectin-rich astrocytic network, which provides 
a transient and focally distributed matrix for endothelial tip cell 
guidance in combination with soluble chemotactic gradients (i.e., 
VEGF) (28, 36). Defective filopodia formation in tip cells lack-
ing GRK2 expression might underpin delayed advance of ECs 
over a retinal astrocytic template, without interfering with the 
potential for migration toward gradients of soluble or nonfo-
cal chemotactic factors that can be less affected by the number/
length of cellular filopodia.
In addition, GRK2 downregulation in ECs alters the endothelial 
barrier function and causes defective tube formation on Matrigel, 
a process that depends on profuse cellular polarization and mor-
phogenetic rearrangements. Consistently, in vivo angiogenesis in 
response to FGF2, VEGF, or S1P was markedly impaired in both 
global and endothelium-specific Grk2+/– mice, with unstructured 
vessels and the presence of disperse aggregations of separate peri-
cytes and ECs. The recruitment of mesenchymal cells into new ves-
sels and their interaction with ECs is mediated by tightly controlled 
gradients of different factors. PDGF-BB facilitates recruitment to 
vessels by binding to PDGFR-β on pericytes (9) and through stim-
ulation of endothelial production of the pericyte chemoattractant 
CXCL12 (37). Notably, aberrant endothelial secretion of PDGF-BB 
and of CXCL12 was found in Grk2+/– MLECs. Overall, these results 
indicate that adequate levels of GRK2 are important not only for 
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ture, and maturity are important factors affecting tumor growth 
(2, 30). Poor vascularization has been suggested to lead to excessive 
hypoxia, which in turn can impel tumor cells to acquire new growth 
and invasive capabilities (50). Moreover, there is an inverse correla-
tion between the extent of pericyte coverage of tumor vessels and 
tumor growth progression (43, 51, 52). Immature vascular plex-
uses induced by high-PDGF-BB–secreting cancerous cells promote 
accelerated rates of tumor growth (52). In line with these studies, 
vessels of tumors growing in Tie2Cre-Grk2fl/– mice were also less 
covered by pericytes compared with those in WT animals, and 
tumors grown in Tie2Cre-Grk2fl/fl animals displayed higher infiltra-
tion of macrophages and a marked increase of hypoxia and adreno-
medullin, known to contribute to enhance tumor progression (53). 
Thus, our data strongly suggest that the decreased pericyte cover-
age promoted by GRK2 downregulation in the endothelium would 
lead to leaky tumor vascularization and consequent hypoxia. This 
situation, together with the fact that the conditioned media of ECs 
lacking GRK2 display an enhanced ability to trigger macrophage 
migration and an altered secretory profile of CXCL12 and other 
macrophage regulatory factors, would favor attraction, rolling, and 
diapedesis of macrophages (refs. 54, 55, and Supplemental Figure 
7C). Given that tumor-associated macrophages support malignant 
proliferation, survival, angiogenesis, and stroma remodeling (31), 
their increased presence would contribute to the higher rate of 
tumor growth observed in GRK2-deficient mice. Consistent with 
this notion, depletion of endogenous macrophages in Tie2Cre-
Grk2fl/fl mice abrogated the enhanced tumor growth observed in 
these animals compared with that in WT littermates.
Manipulation of tumor-associated angiogenesis represents a 
promising strategy to limit cancer progression. Different antian-
giogenic therapies have been developed, including those targeting 
VEGF, PDGF, or FGF2 signaling pathways (1, 2). Because these 
pathways also regulate normal vascular remodeling, it is impor-
tant to identify both new specific signaling cascades in tumor 
angiogenesis and tumoral vessel markers in order to increase 
specificity of anticancer treatments. Our data reveal that EC 
GRK2 is decreased during tumoral, but not normal, angiogen-
esis, suggesting that GRK2 downmodulation could represent a 
novel marker for pathological vasculature. In fact, we report that 
vessels of different breast carcinoma tumors display decreased 
GRK2 levels. Based on the impact of GRK2 downregulation in 
vessel maturation, we propose that tumor-driven downregulation 
of endothelial GRK2 could alter the responsiveness of those ves-
sels sprouting or co-opted within the tumor mass, resulting in an 
intrinsically altered angiogenic response characterized by exces-
sive endothelial activation, defective transition to maturation, and 
pericyte detachment. Such tumor-liable endothelia will respond to 
the extrinsic imbalance of angiogenic factors released by tumors 
cells, further stimulating a continuously remodeled vasculature 
that is unable to mature, thereby giving rise to more permeant ves-
sels that ultimately favor tumor growth and dissemination. It has 
been proposed that pericytes can function as gatekeepers of tumor 
intravasation (30) and that some antiangiogenic therapies can sec-
ondarily disrupt pericyte-endothelial interactions, which results 
in more aggressive tumors (2, 30). Therefore, strategies aiming to 
reestablish normal vessel architecture could increase perfusion 
and reduce local invasiveness and cell intravasation (56). In this 
regard, prevention of GRK2 downregulation in the tumor vascu-
lature would be predicted to facilitate pericyte coverage, switching 
ECs toward maturation and vessel stabilization.
or CXCL12, by GRK2-deficient ECs could disturb local gradients 
needed to drive an adequate intercellular apposition of pericytes 
(42, 43). More recently, similar to the features of retinal vascular-
ization observed in Tie2Cre-Grk2fl/fl animals, it has been reported 
that functional downplay of coating pericytes causes increased 
retinal vessel density and defective vessel regression in the absence 
of differences in pericyte recruitment/coverage (41). Overall, this 
evidence indicates that impaired functional interplay between 
ECs and pericytes during retinal vasculature development might 
underpin deficient vessel remodeling and maturation.
Such altered functional interaction between endothelial and 
mural cells is also detected in other physiological contexts. We 
report that global GRK2 knockout mouse embryos display marked 
vascular malformations, with blood vessels of increased size and 
irregular contours. Strikingly, the endothelia of GRK2-deficient 
mice were almost devoid of mural cell recruitment, which is deter-
minant for vessel maturation. Such defects in pericyte and smooth 
muscle cell coating appear to be secondary to a general endothelial 
dysfunction and not a result of defects in pericyte specification, 
proliferations or mobilization, since Grk2+/– VSMCs display even 
higher migration rates toward PDGF than WT cells, in agreement 
with previous data (13), and no angiogenic phenotype has been 
described in mice with specific GRK2 deletion in VSMCs (15). 
Moreover, endothelium-specific ablation of GRK2 also results 
in a leaky vasculature with defective covering of SMCs and peri-
cytes. Even though SMA-positive cells migrate into the surround-
ing mesenchyme of vessels in Grk2–/– mice, they fail to adequately 
contact ECs. This suggests that the normal gradients of pericyte-
attracting signals derived from endothelial cells could be altered. 
Remarkably, similar vascular phenotypes have been reported in the 
ALK1 (39), endoglin (44), and Smad5 knockout mice (45) or in 
mice with ablated PDGF-BB/PDGFRβ axes (9). Vascular abnor-
malities in Alk1–/– mice may result from the persistence of the acti-
vation phase of angiogenesis (39). Our results would strengthen 
such notion, as GRK2 depletion in ECs promotes hypofunctional-
ity of the ALK1/Smad5 signaling axis in parallel to an immature 
endothelial phenotype.
Global ablation of GRK2 results in embryonic lethality from 
E10.5 and is associated with generalized growth retardation and 
cardiac hypoplasia, although cardiac myocardial-specific knock-
out animals are viable (46, 47). In contrast, endothelial-specific 
ablation of GRK2 results in viable mice, despite the occurrence 
of similar vascular alterations. Although we cannot rule out that 
nonendothelial components in Grk2–/– embryos promote an 
extrafunctional deterioration of their vasculature to cause lethal-
ity in a completely vascular-dependent manner, viability of GRK2 
endothelial-knockout mice suggests that lethality of the former 
requires vascular-independent events. In this regard, it has been 
reported that GRK2 regulates cell cycle in different ways (7, 48) 
and that its presence is mandatory for cell cycle checkpoints and 
Smoothened-dependent proliferation and patterning during 
embryonic development (48, 49).
GRK2 downregulation in ECs reduces pericyte coverage of tumoral vessels 
and potentiates tumor progression. Pathological vascular remodeling 
is critical for the progression of many diseases, including cancer. 
Interestingly, we found that accelerated xenograft tumor progres-
sion, compared with that in WT animals, occurs upon global sys-
temic hemizygosity and endothelium-restricted GRK2 downregula-
tion, along with immature tumor vessel architecture and increased 
vessel perimeter and tortuosity. Microvascular density, architec-
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(Progression TMA breast carcinoma catalog CC08-00, Biomax, Cybrdi) and 
from patients recruited at the Hospital Universitario La Paz after approval by 
the Ethics Committee for Clinical Research of this institution.
Statistics. Data in all figures are expressed as mean ± SEM. All results were 
confirmed in at least 2 separate experiments. Data were analyzed using 
Student’s t test. Two-tailed P < 0.05 was considered statistically significant.
Study approval. The different transgenic mouse models used in this study 
were housed and bred following all established regulatory standards, and 
all the experiments were performed in accordance with guidelines of the 
European Convention for the Protection of Vertebrate Animals used for 
Experimental and Other Scientific Purposes (Directive 86/609/EEC) and 
with the authorization of the Bioethical Committee of the Universidad 
Autónoma de Madrid. Breast cancer samples from patients recruited at 
the Hospital Universitario La Paz were used for immunochemistry stud-
ies after approval by the Ethics Committee for Clinical Research of this 
institution. At the time of surgical patients were informed and provided 
consent that the excess of the resected sample could be used for research 
purposes after diagnosis completion. A specific written consent from 
patients to participate in this particular study was not necessary since no 
additional sample was collected.
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Overall, our data suggest that GRK2 downregulation would be a 
relevant event in the angiogenic switch triggered by tumor cells by 
favoring a permissive microenvironment for tumor progression. 
Notably, GRK2 levels are also altered in different malignant mam-
mary cell lines (57), and enhanced GRK2 levels increase epithelial 
cell motility (34, 58), stressing that cell type–specific modulation 
of this kinase may participate in cancer development. As tumor 
progression is the result of the interplay between malignant cells 
themselves and their surrounding microenvironment, our results 
suggest that opposite changes in GRK2 expression may occur in 
transformed epithelial cells and in the tumor endothelium to syn-
ergistically promote tumor cell invasiveness and intravasation.
Methods
Animal experiments. Systemic GRK2 knockout mice (which die at early ges-
tational age) and animals hemizygous for this kinase (Grk2+/– animals) have 
been generated previously (46). Endothelium-specific GRK2 knockout mice 
(Tie2Cre-Grk2fl/fl mice) were generated by mating GRK2-floxed mice (Grk2fl/fl 
mice) (47) and transgenic endothelial Tie2Cre animals, in which expression 
of Cre recombinase is driven by the endothelial-specific promoter of the 
Tek (Tie2) receptor. We also generated “hybrid” animal models, in which 
individual animals express different extraendothelial GRK2 protein levels 
in combination with distinct endothelial GRK2 content, by crossbreeding 
systemic hemizygous (Grk2+/–) mice with endothelial-restricted knockout 
Tie2Cre-Grk2fl/fl mice. These animal models, the Matrigel plug assay for 
assessing angiogenesis in vivo, and tumor implantation and characteriza-
tion are described in detail in the Supplemental Methods.
Cell culture and coculture assays. MCF7, Hs578T, RAW267.4, and B16F10 
cells (ATCC) were maintained in DMEM supplemented with 10% (v/v) 
fetal bovine serum at 37°C in a humidified 5% CO2 atmosphere. 184B5 
cells were cultured in DMEM/F12-HAMS medium containing 5% horse 
serum, 10 μg/ml insulin, 20 ng/ml EGF, 100 ng/ml cholera toxin, and 
0.5 μg/ml hydrocortisone. Primary MLECs or VSMCs were obtained from 
mice expressing different dosages of systemic and/or endothelial GRK2, as 
detailed in Supplemental Methods. Cell migration, proliferation, cytokine 
secretion, signaling, and in vitro tube formation assays were performed 
as described in the Supplemental Methods; these are the assays in which 
different transformed (B16F10, MCF7, and Hs578T) and nontransformed 
(184B5) cell lines were cocultured with ECs (MLECs).
Immunohistochemistry. Matrigel plugs, implanted tumors, postnatal retinas, 
embryonic and adult mouse tissues, and human breast cancer samples were 
processed for histological analysis and immunohistochemistry to analyze 
vascular structures, as detailed in the Supplemental Methods, using differ-
ent specific antibodies in order to label mural and ECs populations, GRK2 
and adrenomedullin expression, hypoxic status, or macrophage infiltration. 
Human breast tissue samples were obtained from tissue array collections 
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